Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Carcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4,754 result(s) found for: Carcinoma. Displaying page 1 of 238.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-004465-33 Sponsor Protocol Number: Cox052006 Start Date*: 2006-12-04
    Sponsor Name:Eero Kaasinen
    Full Title: Oral Celecoxib combined with BCG instillation therapy in treatment of carcinoma in situ (CIS), TaG3 and T1 disease of urinary bladder
    Medical condition: invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10005014 Bladder carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021501-20 Sponsor Protocol Number: 2010-021501-20 Start Date*: 2010-06-22
    Sponsor Name:ISTITUTO NEUROLOGICO MEDITERRANEO NEUROMED
    Full Title: study for evaluation of 18F-choline PET/CT efficacy in patients with prostate carcinoma.
    Medical condition: patient with prostate carcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001361-81 Sponsor Protocol Number: ICO-N-2016-01 Start Date*: 2017-02-10
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004406-93 Sponsor Protocol Number: PDD-PC-01 Start Date*: 2007-05-29
    Sponsor Name:Klinikum der Universität München
    Full Title: Photodynamische Diagnostik mit 5-Aminolävulinsäure zur Beurteilung der intraoperativen Absetzungsränder im Rahmen der radikalen Prostatovesikulektomie bei Patienten mit einem Prostatakarzinom
    Medical condition: Patients with prostate carinoma who will undergo radical prostatectomy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019260-37 Sponsor Protocol Number: CCRC_2010/001 Start Date*: 2010-07-21
    Sponsor Name:Cork Cancer Research Centre
    Full Title: Electrochemotherapy versus conventional surgery in treatment of basal cell carcinoma
    Medical condition: Basal cell carcinoma of the skin
    Disease: Version SOC Term Classification Code Term Level
    12.1 10004146 Basal cell carcinoma LLT
    12.1 10004148 Basal cell carcinoma excision LLT
    12.1 10004149 Basal cell carcinoma skin excision LLT
    12.1 10024542 Lip basal cell carcinoma LLT
    12.1 10027492 Metatypical basal cell carcinoma LLT
    12.1 10027981 Morpheaform basal cell carcinoma LLT
    12.1 10029496 Nodulo-ulcerative basal cell carcinoma LLT
    12.1 10035029 Pigmented basal cell carcinoma LLT
    12.1 10039716 Sclerosing basal cell carcinoma LLT
    12.1 10042503 Superficial basal cell carcinoma LLT
    12.1 10062787 Morphoeaform basal cell carcinoma LLT
    12.1 10064679 Basal cell carcinoma of skin in situ LLT
    12.1 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002299-92 Sponsor Protocol Number: 54/2008/U/Sper Start Date*: 2008-06-24
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: METRONOMIC CAPECITABINE IN ADVANCED HEPATOCARCINOMA: A FASE II STUDY
    Medical condition: Advanced Hepatocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002546-11 Sponsor Protocol Number: HAN-HCC-002 Start Date*: 2006-10-20
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: Offene Phase IIIb Studie zur Elimination von CD4+CD25+ regulatorischen T-Zellen bei Patienten mit fortgeschrittenem HCC durch die Gabe von Cyclophosphamid
    Medical condition: Fortgeschrittenes Leberzellkarzinom
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005976-15 Sponsor Protocol Number: CCR3024 Start Date*: 2008-03-27
    Sponsor Name:Royal Marsden Hospital NHS Trust
    Full Title: A randomised open-labelled multicentre trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancer ...
    Medical condition: Advanced (Inoperable locally advanced, metastatic or recurrent) , histologically verified adenocarcinoma or undifferentiated carcinoma of the oesophagus, oesophagogastric junction or stomach.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017770 Gastric carcinoma LLT
    9.1 10030155 Oesophageal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002120-83 Sponsor Protocol Number: ICO-N-2016-02 Start Date*: 2016-10-05
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEAU
    Full Title: Study evaluation of 2nd hormone line response by -[18F]fluoro-17β-œstradiol (FES) PET/CT in metastatic breast cancer patients
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10007305 Carcinoma breast LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015237-76 Sponsor Protocol Number: LUC 09-002 Start Date*: 2010-04-26
    Sponsor Name:Centre du Cancer des Cliniques Universitaires Saint-Luc
    Full Title: An open label multicentric phase II study of Panitumumab (Vectibix®) in cutaneous squamous cell carcinoma (SCC)
    Medical condition: Cutaneous Squamous Cell Carcinoma (SCC)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10041823 Squamous cell carcinoma LLT
    12.1 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000252-34 Sponsor Protocol Number: CA2099DW Start Date*: 2020-02-17
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049010 Carcinoma hepatocellular LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Trial now transitioned) BE (Ongoing) AT (Trial now transitioned) IT (Ongoing) RO (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002586-36 Sponsor Protocol Number: PACT-9 Start Date*: 2005-07-01
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: PEXG VERSUS PDXG IN LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA : RANDOMIZED, PHASE II STUDY.
    Medical condition: PANCREAS TUMOR TREATMENT
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033609 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012576-27 Sponsor Protocol Number: SORAMIC Start Date*: 2010-04-09
    Sponsor Name:Medical Faculty, University Magdeburg
    Full Title: Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma
    Medical condition: Patients with Hepatocellular carcinoma (liver-predominant disease)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    20.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    20.0 100000004864 10049010 Carcinoma hepatocellular LLT
    20.0 100000004864 10019830 Hepatocellular carcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) AT (Completed) ES (Completed) BE (Ongoing) PL (Completed) SI (Completed) IT (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003992-35 Sponsor Protocol Number: MREC02/8/71 Start Date*: 2009-12-16
    Sponsor Name:Queen Mary University of London
    Full Title: International Breast Cancer Intervention Study II (DCIS). An international multi-centre trial of tamoxifen v anastrozole in post-menopausal women with ductal carcinoma in situ.
    Medical condition: Ductal carcinoma in situ
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10013806 Ductal carcinoma in situ LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000781-23 Sponsor Protocol Number: GEN207 Start Date*: 2008-06-09
    Sponsor Name:Genmab A/S
    Full Title: An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination wi...
    Medical condition: Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based Chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023860 Laryngeal squamous cell carcinoma stage III LLT
    9.1 10023861 Laryngeal squamous cell carcinoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012570-13 Sponsor Protocol Number: BAY73-4506/14596 Start Date*: 2009-08-25
    Sponsor Name:Bayer HealthCare AG, D51368 Leverkusen
    Full Title: An uncontrolled open label multicenter phase II safety study of BAY 73-4506 in patients with hepatocellular carcinoma (HCC)
    Medical condition: Hepatocellular carcinoma, in patients who have failed (experienced radiological progression) previous treatment cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001623-18 Sponsor Protocol Number: EGF102988 Start Date*: 2006-12-07
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or P...
    Medical condition: Resected Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041823 Squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IE (Completed) GR (Completed) AT (Completed) SK (Completed) GB (Completed) DE (Completed) CZ (Completed) PT (Prematurely Ended) EE (Completed) HU (Completed) IT (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003833-24 Sponsor Protocol Number: AGMT_HNO_PN Start Date*: 2016-06-30
    Sponsor Name:AGMT – Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: Randomized phase III study: Supplemental parenteral nutrition for patients with locally advanced inoperable tumors of the head and neck, receiving definitive radiotherapy with Cetuximab or Cisplatin
    Medical condition: Locally advanced inoperable tumors of the head and neck under definitive radiotherapy with Cetuximab or Cisplatin
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10031117 Oropharyngeal squamous cell carcinoma stage III LLT
    20.0 100000004864 10041862 Squamous cell carcinoma of the oral cavity stage III LLT
    20.0 100000004864 10041863 Squamous cell carcinoma of the oral cavity stage IV LLT
    20.0 100000004864 10031103 Oropharyngeal cancer stage unspecified LLT
    20.0 100000004864 10041855 Squamous cell carcinoma of the hypopharynx stage IV LLT
    20.0 100000004864 10023860 Laryngeal squamous cell carcinoma stage III LLT
    20.0 100000004864 10041854 Squamous cell carcinoma of the hypopharynx stage III LLT
    20.0 100000004864 10023861 Laryngeal squamous cell carcinoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000782-35 Sponsor Protocol Number: 28-02 (ZKS000429) Start Date*: 2009-01-21
    Sponsor Name:Verein fuer Krebsfoschung (Society for Cancer Research)
    Full Title: Dose-escalating study to determine the maximum tolerated dose (MTD) of the mistletoe extract WEME 200 mg for intravesical instillation in patients with completely resected (R0) superficial bladder ...
    Medical condition: Patients after transurethral R0-resection (TUR) of a histologically confirmed superficial bladder carcinoma (pTa low grade [multilocular or recurrence], pT1 low grade); re-resections included.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046518 Urinary bladder carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002727-11 Sponsor Protocol Number: CRO-2020-043 Start Date*: 2023-08-02
    Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO
    Full Title: Neoadjuvant Chemotherapy followed by Pre-operative Chemoradiation and Consolidation Chemotherapy before Surgery in High Risk Rectal Cancer: Multicentric Phase II Study.
    Medical condition: Patients with locally advanced, potentially resectable, Middle-Distal Rectal Carcinoma, stage T3c-d N1-2, MRF + or T4N0-2, EMVI - / + (High-Risk)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007464 Carcinoma rectum LLT
    20.0 100000004864 10038052 Rectal carcinoma LLT
    20.0 100000004864 10007446 Carcinoma of rectum LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 04:33:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA